The Vanguard Group 13D and 13G filings for Oruka Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 11:04 am Sale | 2026-03-13 | 13G | Oruka Therapeutics, Inc. ORKA | The Vanguard Group | 0 0.000% | -2,453,530 (Position Closed) | Filing |
| 2026-01-30 2:20 pm Purchase | 2025-12-31 | 13G | Oruka Therapeutics, Inc. ORKA | The Vanguard Group | 2,453,530 5.060% | 2,453,530 (New Position) | Filing |